Unfortunately, most patients require multiple medications to obtain glycemic control.
To obtain glycemic control (e.g. HbA1c<7.5%), T2D patients benefit from measures to improve insulin sensitivity such as diet and exercise management [ 4].
Controlling total carbohydrate intake with either an exchange diet or the carbohydrate count is a key strategy to obtain glycemic control in patients under insulin therapy with a daily multidose pattern (basal-bolus).
Tables 2 and 3 depict the most important results of GLP-1 and GLP-1R agonists from animal and human studies mentioned in the text.>> The potential cardiovascular benefits expected from this new therapeutic approach to obtain glycemic control in T2D arises a possibility to change the excessive cardiovascular burden related to this disease in both developed and developing countries worldwide.
Type 2 diabetic (n = 306) patients who failed to obtain glycemic control (A1C 7 9.5%) despite 1,500 mg metformin daily were randomly assigned to 8 weeks of double-blind subcutaneous treatment with placebo or taspoglutide, either 5, 10, or 20 mg once weekly or 10 or 20 mg once every 2 weeks, and followed for 4 additional weeks.
So far, no single IIP has been established as the most effective for obtaining tight glycemic control.
Up till now no single IIP has been established as the most effective for obtaining tight glycemic control [28, 39, 40].
However, the literature indicates that physicians taking care of diabetic patients with CVD might face multiple obstacles for obtaining adequate glycemic control.
Diabetes mellitus, the well-recognized CVD risk equivalent [ 7, 8], where obtaining tight glycemic control is thought to reduce the enhanced CVD risk [ 9], is exacerbated by the overweight or obese status.
Although many insulin-based regimens have been used safely in elderly patients (Elgrabley et al 1991; Miles et al 1994), hypoglycemia is a concern and challenge for obtaining tighter glycemic control, as mentioned.
